Tagged with CCE

Africa Africa accounts for 19 percent of the world’s population and one-quarter of the global disease burden. However, for a host of reasons – both real and perceptual – the continent does not yet play host to meaningful levels of clinical research, accounting for just 1.1 percent of all clinical trials…

Switzerland Clinigen is in the midst of a major transformation, repositioning itself as a pure services partner focused on bridging patient access to critical medicines worldwide. Its recent acquisition of SSI Strategy underscores this shift, combining SSI’s strategic depth, established U.S. and European footprint, and innovative partnership models with Clinigen’s global…

France With only a handful of patients affected by each condition, rare diseases present a unique set of scientific, medical, and economic challenges. At the heart of this complex landscape is Recordati Rare Diseases, whose European headquarters and manufacturing footprint are anchored in France. General Manager Jean-Claude Roche shares his perspective…

Denmark Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche service providers, and a growing throng of biotech start-ups. And with life science exports surpassing EUR 23 billion last year…

Europe Affordability is not necessarily the main barrier to better rare disease therapy access in Europe. Across the continent, orphan availability correlates poorly with GDP per capita, but strongly with health technology assessment methods, speed of pricing and reimbursement, and central vs regional decision-making. Better system design – rather than simply…

Switzerland Giancarlo Benelli, SVP, Head of Europe at BeOne Medicines (BeOne), draws on nearly three decades of pharmaceutical leadership to drive the company’s rapid growth in oncology and haematology in Europe, with flagship assets like zanubrutinib and tislelizumab. Over the last few years, BeOne has greatly expanded its clinical trials in…

Hong Kong Since our last conversation with Tony Cheng in mid-2024, Merck Hong Kong has entered a new phase of consolidation and growth. The affiliate has strengthened its team, accelerated its adoption of AI, and deepened collaborations with the Hong Kong Science and Technology Parks. At the same time, Cheng continues to…

Alexion Dana Vigier, Regional Vice President at Alexion, AstraZeneca Rare Disease blends clinical training as a French general practitioner with broad pharmaceutical leadership experience. Formerly President of the French Pharma Association in Oncology and a Global Franchise leader at AstraZeneca, she now oversees Alexion’s operations across Central and Northern Europe, including…

USA John Murphy, President and CEO of the Association for Accessible Medicines (AAM), outlines a compelling vision for improving access to high-quality, affordable medicines in the US. He stresses that by directing greater focus to the generic and biosimilar market, tackling structural challenges, safeguarding supply chains, and enabling strategic domestic investment,…

Switzerland FarmaMondo’s evolution over the past eight years is a compelling case study in what it takes to bring life-saving innovation to the world’s most overlooked patients, not through philanthropy but through a commercially sustainable, ethically grounded model. Operating from a Swiss base with deep roots in legal rigour and regulatory…

Americas In a world where medical innovation is accelerating, Latin America–a region of some 662 million people—is falling dangerously behind. Patients face wait times of up to 5.6 years to access life-saving therapies already available elsewhere. This is not merely a delay, but a systemic failure rooted in chronic underinvestment and…

LatAm Yaneth Giha, Executive Director of FIFARMA, has transformed the organisation from a traditional trade association into a strategic platform for advancing healthcare access in Latin America. The first woman to lead FIFARMA, she drives evidence-based solutions, multi-stakeholder collaboration, and regulatory reform, positioning the region as a rising force in global…